The Diagnostic Potential of Radiolabelled Neurotensin in PET Imaging of Patients with Pancreatic Cancer: Results from In Vivo, Animal And Human Studies
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F22%3A73611072" target="_blank" >RIV/61989592:15110/22:73611072 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.eurekaselect.com/chapter/16573" target="_blank" >https://www.eurekaselect.com/chapter/16573</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/9781681088655122010010" target="_blank" >10.2174/9781681088655122010010</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Diagnostic Potential of Radiolabelled Neurotensin in PET Imaging of Patients with Pancreatic Cancer: Results from In Vivo, Animal And Human Studies
Popis výsledku v původním jazyce
In nuclear medicine, multiple peptide receptors are recognized as potential diagnostic and therapeutic targets. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. Three neurotensin receptors subtypeshave been cloned: NTR-1, NTR-2 and NTR-3. NTR-1 is the most commonly expressed neurotensin receptor. High NTR-1 expression has been observed in various tumours including pancreatic ductal adenocarcinoma. 68Ga-labelled NT ligand was successfullyapplied in in vitro, animal model as well as in human. The results on humans demonstrated that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated. Based on the published data, NTR-1 is promising target for the development ofradioactive analogues for both imaging and therapy in patients with primary and metastatic pancreatic ductal adenocarcinoma.
Název v anglickém jazyce
The Diagnostic Potential of Radiolabelled Neurotensin in PET Imaging of Patients with Pancreatic Cancer: Results from In Vivo, Animal And Human Studies
Popis výsledku anglicky
In nuclear medicine, multiple peptide receptors are recognized as potential diagnostic and therapeutic targets. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. Three neurotensin receptors subtypeshave been cloned: NTR-1, NTR-2 and NTR-3. NTR-1 is the most commonly expressed neurotensin receptor. High NTR-1 expression has been observed in various tumours including pancreatic ductal adenocarcinoma. 68Ga-labelled NT ligand was successfullyapplied in in vitro, animal model as well as in human. The results on humans demonstrated that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated. Based on the published data, NTR-1 is promising target for the development ofradioactive analogues for both imaging and therapy in patients with primary and metastatic pancreatic ductal adenocarcinoma.
Klasifikace
Druh
C - Kapitola v odborné knize
CEP obor
—
OECD FORD obor
30224 - Radiology, nuclear medicine and medical imaging
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název knihy nebo sborníku
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
ISBN
978-1-68108-866-2
Počet stran výsledku
10
Strana od-do
"91 "- 100
Počet stran knihy
525
Název nakladatele
Bentham Science Publishers
Místo vydání
Bussum
Kód UT WoS kapitoly
—